Two large clinical trials in North America and Europe involving over 1, women were conducted to evaluate the effectiveness of anastrozole compared to tamoxifen. All women had estrogen receptor positive advanced breast cancer.
Half of the women received anastrozole and the other half received tamoxifen. Outcomes between the 2 groups were then directly compared.
Patients receiving anastrozole achieved a higher rate of partial or complete cancer disappearance compared to patients receiving tamoxifen. In addition, time to cancer progression was delayed for a longer period of time in patients receiving anastrozole compared to those receiving tamoxifen.
These results demonstrate the efficacy of anastrozole for treatment of women with estrogen receptor positive breast cancer. Post-menopausal women with advanced estrogen receptor positive breast cancer may wish to speak with their doctor about the use of anastrozole or about the risks and benefits of participating in a clinical trial evaluating other promising hormonal treatment strategies.
All Rights Reserved. Hodgkins Lymphoma. Multiple Myeloma. Myelodysplastic Syndrome. Neuroendocrine Tumors. Anastrozole demonstrated a statistically significantimprovement in recurrence-free survival compared to tamoxifen. Anderson Cancer Center, Houston.
The safety and tolerability of both anastrozole and tamoxifenwere evaluated in the ATAC trial in 3, patients taking tamoxifen and 3,patients taking anastrozole. Endometrial cancer occurred at a rate of0. Angina pectoris was reported more frequently in anastrozole-treatedpatients 1. The FDA made its decision after evaluating results of clinical studies involving more than subjects. Results from the two studies showed that Arimidex is effective in the treatment of advanced breast cancer.
Most commonly reported side effects, regardless of causality, included fatigue, nausea, headache, hot flashes, pain and back pain. Arimidex is not associated with significant weight gain reported with progestins. Results from studies suggest that growth of some breast cancer tumors is stimulated by the female hormone estrogen. Arimidex, a nonsteroidal compound, is the first entry in a new class of third-generation selective oral aromatase inhibitors.
Inhibition of aromatase reduces the production of estrogen.
0コメント